TABLE II.

Pivotal studies of chimeric antigen receptor T cell therapy in relapsed or refractory diffuse large B cell lymphoma

Treatment	Reference (study name)	Phase	Patients
			(n)	Details
Axicabtagene ciloleucel	Locke et al., 201956 and Neelapu et al., 201824 (ZUMA-1)	I/II	108	▪ Median 3 prior therapy lines
	Efficacy in DLBCL ▪ Median follow-up: 27.1 months ▪ Median progression-free survival: 5.9 months; median overall survival: not reached; best overall response rate: 83%; best complete response: 58%; median duration of response: 11.1 months Safety ▪ Grade 3 or greater adverse events: cytokine release syndrome, 11%; neurotoxicity, 32%; neutropenia, 39%; anemia, 45%; thrombocytopenia, 24%
	Jacobson et al., 201857	Real-world setting	76	▪ 36 with DLBCL ▪ Prior therapy lines not given
	Efficacy in DLBCL▪ Median follow-up: 4 months; best overall response rate: 64%a; best complete response: 41%aSafety▪ Grade 3 or greater adverse events: cytokine release syndrome, 17%; neurotoxicity, 38%
	Nastoupil et al., 201858	Real-world setting	211	▪ 61% with DLBCL ▪ Prior therapy lines not given
	Efficacy in DLBCL ▪ Median follow-up: not given ▪ 1-Month overall response rate: 79%; 1-month complete response: 50% Safety ▪ Grade 3 or greater adverse events: cytokine release syndrome, 7%; neurotoxicity, 31%
Lisocabtagene maraleucel	Abramson et al., 201825 (TRANSCEND)	I	91	▪ Median 3 prior therapy lines
	Efficacy in DLBCL ▪ Median follow-up: not given ▪ Best overall response rate: 74%a; best complete response: 52%a Safety ▪ Grade 3 or greater adverse events: cytokine release syndrome, 1%; neurotoxicity, 12%
Tisagenlecleucel	Schuster et al., 201959 (JULIET)	II	93	▪ More than 3 prior therapy lines in 21% ▪ Median time from infusion to data cut-off: 14 months
	Efficacy in DLBCL ▪ Median progression-free survival: not reported; median overall survival: 12 months; best overall response rate: 52%a; best complete response: 40%a; median duration of response: not reached Safety ▪ Grade 3 or greater adverse events: cytokine release syndrome, 22%; neurotoxicity, 12%; cytopenias for more than 28 days: 32%; infections, 20%; febrile neutropenia, 14%

^aRecorded from study start to disease progression.

DLBCL = diffuse large B-cell lymphoma.